Literature DB >> 18184972

Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas.

Aiguo Li1, Jennifer Walling, Yuri Kotliarov, Angela Center, Mary Ellen Steed, Susie J Ahn, Mark Rosenblum, Tom Mikkelsen, Jean Claude Zenklusen, Howard A Fine.   

Abstract

Genetic aberrations, such as gene amplification, deletions, and loss of heterozygosity, are hallmarks of cancer and are thought to be major contributors to the neoplastic process. Established cancer cell lines have been the primary in vitro and in vivo models for cancer for more than 2 decades; however, few such cell lines have been extensively characterized at the genomic level. Here, we present a high-resolution genome-wide chromosomal alteration and gene expression analyses of five of the most commonly used glioma cell lines and compare the findings with those observed in 83 primary human gliomas. Although genomic alterations known to occur in primary tumors were identified in the cell lines, we also observed several novel recurrent aberrations in the glioma cell lines that are not frequently represented in primary tumors. Additionally, a global gene expression cluster distinct from primary tumors was identified in the glioma cell lines. Our results indicate that established cell lines are generally a poor representation of primary tumor biology, presenting a host of genomic and gene expression changes not observed in primary tissues, although some discrete features of glioma biology were conserved in the established cell lines. Refined maps of genetic alterations and transcriptional divergence from the original tumor type, such as the one presented here, may help serve as a guideline for a more biologically rational and clinically relevant selection of the most appropriate glioma model for a given experiment.

Entities:  

Mesh:

Year:  2008        PMID: 18184972     DOI: 10.1158/1541-7786.MCR-07-0280

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  123 in total

1.  The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells.

Authors:  Muhammad Jamal; Barbara H Rath; Patricia S Tsang; Kevin Camphausen; Philip J Tofilon
Journal:  Neoplasia       Date:  2012-02       Impact factor: 5.715

2.  Predicting in vitro drug sensitivity using Random Forests.

Authors:  Gregory Riddick; Hua Song; Susie Ahn; Jennifer Walling; Diego Borges-Rivera; Wei Zhang; Howard A Fine
Journal:  Bioinformatics       Date:  2010-12-05       Impact factor: 6.937

3.  Microenvironmental regulation of glioblastoma radioresponse.

Authors:  Muhammad Jamal; Barbara H Rath; Eli S Williams; Kevin Camphausen; Philip J Tofilon
Journal:  Clin Cancer Res       Date:  2010-10-29       Impact factor: 12.531

4.  Sorafenib exerts anti-glioma activity in vitro and in vivo.

Authors:  Markus D Siegelin; Christopher M Raskett; Candace A Gilbert; Alonzo H Ross; Dario C Altieri
Journal:  Neurosci Lett       Date:  2010-05-12       Impact factor: 3.046

5.  Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma.

Authors:  Alice M Walsh; Gurpreet S Kapoor; Janine M Buonato; Lijoy K Mathew; Yingtao Bi; Ramana V Davuluri; Maria Martinez-Lage; M Celeste Simon; Donald M O'Rourke; Matthew J Lazzara
Journal:  Mol Cancer Res       Date:  2015-05-01       Impact factor: 5.852

6.  Transcriptional changes associated with in vivo growth of muscle-invasive bladder cancer cell lines in nude mice.

Authors:  Swathi Ramakrishnan; Wendy Huss; Barbara Foster; Joyce Ohm; Jianmin Wang; Gissou Azabdaftari; Kevin H Eng; Anna Woloszynska-Read
Journal:  Am J Clin Exp Urol       Date:  2018-06-15

7.  Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules.

Authors:  Rutger K Balvers; Anne Kleijn; Jenneke J Kloezeman; Pim J French; Andreas Kremer; Martin J van den Bent; Clemens M F Dirven; Sieger Leenstra; Martine L M Lamfers
Journal:  Neuro Oncol       Date:  2013-09-17       Impact factor: 12.300

8.  Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells.

Authors:  Christine E Brown; Renate Starr; Catalina Martinez; Brenda Aguilar; Massimo D'Apuzzo; Ivan Todorov; Chu-Chih Shih; Behnam Badie; Michael Hudecek; Stanley R Riddell; Michael C Jensen
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

9.  High-Throughput Screening of Patient-Derived Cultures Reveals Potential for Precision Medicine in Glioblastoma.

Authors:  Christine E Quartararo; Eduard Reznik; Ana C deCarvalho; Tom Mikkelsen; Brent R Stockwell
Journal:  ACS Med Chem Lett       Date:  2015-06-22       Impact factor: 4.345

10.  Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.

Authors:  Shiv K Gupta; Sani H Kizilbash; Brett L Carlson; Ann C Mladek; Felix Boakye-Agyeman; Katrina K Bakken; Jenny L Pokorny; Mark A Schroeder; Paul A Decker; Ling Cen; Jeanette E Eckel-Passow; Gobinda Sarkar; Karla V Ballman; Joel M Reid; Robert B Jenkins; Roeland G Verhaak; Erik P Sulman; Gaspar J Kitange; Jann N Sarkaria
Journal:  J Natl Cancer Inst       Date:  2015-11-27       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.